Key result
SGLT2 inhibitors linked to a ~55% lower 12-month AF recurrence risk after catheter ablation.
Why the study?
Does SGLT2 inhibitor use reduce 12-month atrial fibrillation recurrence in patients undergoing first-time catheter ablation?
Population
430 AF patients undergoing first-time cardiac radiofrequency CA
Comparison
SGLT2i (10mg daily dapagliflozin/empagliflozin) vs control
Design
Single-center prospective observational cohort study with propensity score matching
Follow-up
12-month
Authors
Loading...
May warrant SGLT2i post-AF ablation in eligible patients; extends prior evidence but leaves open benefit pending RCTs.
Cohort (n=430)
Does SGLT2 inhibitor use reduce 12-month atrial fibrillation recurrence in patients undergoing first-time catheter ablation?
Effect estimate: HR 0.450 (95% CI 0.217-0.932)
p-value: p=0.032
Postoperative SGLT2 inhibitor use is associated with a significantly lower 12-month risk of atrial fibrillation recurrence following first-time radiofrequency catheter ablation.
Huang et al. (2026) conducted a cohort in Atrial Fibrillation (n=430). SGLT2 Inhibitors vs. Control was evaluated on 12-month recurrence of atrial fibrillation (HR 0.450, 95% CI 0.217-0.932, p=0.032). SGLT2 inhibitors significantly reduced the 12-month recurrence risk of atrial fibrillation after catheter ablation compared to the control group (aHR 0.450).